NCT01760681Unknown不适用
A Randomized Sham-Controlled Study of H-Coil Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Late-Life Depression
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Improvement in depression symptoms, evaluated by HDRS
研究概览
简要总结
The purpose of the study is to explore the efficacy and safety of H-Coil rTMS in comparison to a sham H-Coil rTMS in older patients with treatment-resistant major depressive disorder.Subjects will be randomized to receive H1-Coil rTMS or sham H1-Coil rTMS. The acute treatment phase will last four weeks. Treatment is administered daily, 5 days per week (i.e., 20 treatments). Depressive symptoms will be assessed using the HDRS-24. If subjects achieve the pre-defined primary outcome criteria of remission (HDRS-24 score < 10 and 60% reduction in symptoms) they will continue with twice weekly treatment for two more weeks to ensure the durability of the remission. Subjects who do not achieve remission will exit the study after the acute treatment phase of four weeks. The blind will not be broken to subjects until the completion of the study
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 60 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •are outpatients
- •are voluntary and competent to consent to treatment
- •have a Structured Clinical Interview for DSM-IV (SCID)103 confirmedn DSM-IV diagnosis of MDD, single or recurrent
- •are between the ages of 60 and 85
- •have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of > 3 in the current episode 104, 105 OR have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF 1 or 2)
- •have a score > 22 on the HDRS-24
- •have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening
- •able to adhere to the treatment schedule
- •Pass the TMS safety screening questionnaire
- •have normal thyroid functioning based on pre-study blood work.
排除标准
- •have a history of DSM-IV substance dependence or abuse within the last 3 months
- •have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump
- •are acutely suicidal
- •are pregnant
- •have a lifetime SCID diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms
- •have a SCID diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder) assessed by a study investigator to be primary and causing greater impairment than MDD
- •have a SCID diagnosis of any personality disorder and assessed by a study investigator to be primary and causing greater impairment than MDD
- •have presumed or probable dementia, as defined by Mini Mental Status Exam (MMSE) < 26 and clinical evidence of dementia. Patients screened out due to possible dementia will be referred to the local memory clinic for evaluation to clarify the presence or absence of dementia
- •have failed a course of ECT within the current depressive episode
- •have received rTMS for any previous indication due to the potential compromise of subject blinding
- •have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 5 minutes
- •on a dose of Buproprion greater than 300mg per day
- •have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
- •if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study
- •clinically significant laboratory abnormality, in the opinion of the investigator
- •currently (or in the last 4 weeks) take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy
- •inability to communicate
- •non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).
结局指标
主要结局
Improvement in depression symptoms, evaluated by HDRS
时间窗: 6-8 weeks
Clinical antidepressant response at the end of the treatment, define as a decline in Hamilton depression rating scale (HDRS-24) from the baseline rating by 50%.
次要结局
- 1. Remission in depression(6-8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Repetitive Transcranial Stimulation (r-TMS) Treatment for Patients With Parkinson's DiseaseParkinson's DiseaseNCT00625300Sheba Medical Center20
已完成
不适用
Deep rTMS for Treatment-Resistant Late-life DepressionMajor Depressive DisorderNCT01860157Centre for Addiction and Mental Health58
Unknown
不适用
A Double Blind Sham-controled Study to Evaluate the Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's DiseaseAsymmetric Parkinson's DiseaseNCT01367782Sheba Medical Center51
Unknown
不适用
Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar DepressionBipolar DepressionNCT01566591Brainsway120
Unknown
不适用
Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar DepressionBipolar DepressionNCT00657735Shalvata Mental Health Center50